GlassScriptPhysician profile
Jonathan Kandiah
NPI 1043662463
$9,000.05
in general payments reported to CMS, 2019-2025
35 companies · $3,975 in 2025
The $3,975 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $809 · 2023: $1,373 · 2024: $2,705 · 2025: $3,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,681 · Travel and Lodging: $2,197 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,681.34 |
| Travel and Lodging | $2,197.49 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,903.70 | 2021-2025 | Axios, Exalt Model D, Overstitch Endoscopic Suturing System |
| Abbvie INC. | $1,352.48 | 2022-2025 | |
| Medtronic, INC. | $1,076.99 | 2025 | Barrx, Endoflip |
| Janssen Biotech, INC. | $778.42 | 2022-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $504.25 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $180.38 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.53 | 2022-2025 | Entyvio, Gattex |
| Genzyme Corporation | $165.49 | 2023-2025 | |
| Enterra Medical, INC. | $153.83 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $143.59 | 2022-2025 | Dupixent |
| Merit Medical Systems INC | $139.10 | 2025 | Esophyx |
| Qol Medical, LLC | $122.29 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $120.61 | 2022-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $103.25 | 2025 | Voquezna |
| Gilead Sciences, INC. | $99.84 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $97.66 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $97.41 | 2022-2025 | Rebyota, Clenpiq |
| Cook Medical LLC | $95.31 | 2022 | |
| Celgene Corporation | $77.82 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $77.65 | 2022-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $66.74 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $61.23 | 2025 | Iqirvo |
| Lilly USA, LLC | $57.82 | 2024-2025 | Omvoh |
| Endogastric Solutions, INC | $55.62 | 2024 | Esophyx |
| Organon LLC | $48.12 | 2023-2025 | Renflexis, Hadlima |
| Alnylam Pharmaceuticals INC. | $43.26 | 2024-2025 | Givlaari |
| Conmed Corporation | $35.26 | 2025 | Conmed Biliary, Conmed Hemostasis |
| Novo Nordisk INC | $32.77 | 2025 | Wegovy |
| Ardelyx, INC. | $28.14 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $20.76 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $19.64 | 2023 | |
| Mallinckrodt Hospital Products INC. | $18.74 | 2023 | Terlivaz |
| Mylan Institutional INC. | $17.67 | 2023 | Hulio |
| Intercept Pharmaceuticals, INC. | $15.80 | 2025 | |
| Redhill Biopharma INC. | $13.88 | 2023 | Aemcolo, Talicia, Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kandiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.